NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases
October 31, 2024 05:00 ET
|
NRG Therapeutics Limited
First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative...
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
September 05, 2024 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, Sept. 05, 2024 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
April 26, 2023 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
April 19, 2023 04:00 ET
|
NRG Therapeutics Limited
Vad Lazari Ph.D., appointed to the newly created position of VP of Biology, based in Stevenage, UKJoins from Charles River and brings two decades of drug discovery experience including at Pfizer and...
NRG Therapeutics Announces International Scientific Advisory Board
March 30, 2023 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of...
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
February 22, 2023 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
February 09, 2023 04:01 ET
|
NRG Therapeutics Limited
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UKJoins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at...